Matter-Walstra, Klazien; Klingbiel, Dirk; Szucs, Thomas; … - In: PharmacoEconomics 32 (2014) 6, pp. 591-599
For Switzerland, utility calculations based on the German or French value set would be an obvious choice. Our results suggest that the German value set may not be the most appropriate for use with Swiss cancer patients. The French and EU value sets may be relevant alternatives and improve...